TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32932231
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 mg caffeine, 0 g sugars)
Study: 35438367
Drug: High fresh
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: High fresh gas flow (HFGF) at 4 L/min with sevoflurane vaporizer setting of 2.5%
Study: 35438367
Drug: Low fresh
Normalized name: Peroxi-Fresh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low fresh gas flow (LFGF) at 1 L/min with sevoflurane vaporizer setting of 8%
Study: 34015228
Drug: Narrow Band
Normalized name: Band-Aid Hurt-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrow Band Ultraviolet B (NBUVB) with 311-313 nm, initial dose of 250 mJ/cm2, thrice a week for 8 weeks
Study: 34058431
Drug: Sub-Tenon injection
Normalized name: tenonitrozole
DrugBank: Tenonitrozole (DB13659)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub-Tenon injection of 0.15 ml of 0.01% MMC diluted with preservative free lidocaine 2% (n = 27)
Study: 32661107
Drug: Glimepiride +
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glimepiride + Linagliptin 5 mg
Study: 35594274
Drug: Minimal acupuncture
Normalized name: Centipeda minima whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal acupuncture treatment (8 sessions over 4 weeks)
Study: 32993769
Drug: IOP-lowering medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: IOP-lowering medication
Study: 33113075
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy (PBMT) with a preventive oral care program (POCP), n = 25
Study: 32894857
Drug: Azithromycin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (10 mg/kg/day for 5 days)
Study: 32839990
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium bicarbonate (4.26 g in 200 mL of water) plus oxytocin
Study: 39415923
Drug: No antithrombotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antithrombotic therapy
Study: 35727042
Drug: Placebo-assisted therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-assisted therapy (Placebo-AT)
Study: 32959996
Drug: High-intensity intervention
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity intervention (weekly multidisciplinary sessions)
Study: 32436242
Drug: Oral ginger
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ginger for dysmenorrhea
Study: 32436242
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and topical ginger for DOMS
Study: 32436242
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and topical ginger for knee AO
Study: 32448159
Drug: School-based annual
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-based annual mass drug administration (MDA) with praziquantel
Study: 34705291
Drug: 81 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 81 mg/day aspirin for 4 weeks
Study: 34705291
Drug: 325 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 325 mg/day aspirin for 4 weeks
Study: 34705291
Drug: Aspirin exposure
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin exposure
Study: 35013093
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of curcumin, resveratrol, zinc, magnesium, selenium, and vitamin D
Study: 34088701
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human parathyroid hormone (PTH) (1-84)
Study: 33218510
Drug: Myofascial induction
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myofascial induction therapy (MIT)
Study: 34957958
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (drug treatments and instrumental physical therapy)
Study: 34913362
Drug: MSC therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSC therapy (infused at weeks 6 and 7 after transplantation, tacrolimus withdrawal at week 8)
Study: 36347387
Drug: Standard tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard tacrolimus dose (control group)
Study: 33259244
Drug: Arm A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm A: vinorelbine 60 mg/m2 day 1 + day 8 in the first cycle followed by 80 mg/m2 day 1 + day 8 in the following cycles + capecitabine 1000 mg/m2 twice a day for days 1–14
Study: 33259244
Drug: Arm B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm B: vinorelbine 50 mg three times a week + capecitabine 1000 mg/m2 twice a day for days 1–14
Study: 34503866
Drug: Fimasartan 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fimasartan 30 mg, increased to 60 mg if BP not controlled, with possible hydrochlorothiazide 12.5 mg combination
Study: 34503866
Drug: Perindopril arginine
Normalized name: Perindopril Arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril arginine 2.5 mg, increased to 5 mg if BP not controlled, with possible indapamide 1.25 mg combination
Study: 34503866
Drug: Fimasartan 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fimasartan 30 to 60 mg with possible hydrochlorothiazide 12.5 mg combination
Study: 34503866
Drug: Perindopril 2.5
Normalized name: amlodipine-perindopril 2.5 mg-3.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 2.5 to 5 mg with possible indapamide 1.25 mg combination
Study: 33545751
Drug: Alprostadil combined
Normalized name: Alprostadil
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alprostadil combined with tanshinone IIa injection (Group C)
Study: 33545751
Drug: Tanshinone IIa
Normalized name: autoprothrombin IIA
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tanshinone IIa injection (Group B)
Study: 32058832
Drug: Preclass preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preclass preparation and student accountability as part of TBL
Study: 32053137
Drug: Pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab plus neoadjuvant chemotherapy (4 cycles of pembrolizumab in combination with weekly paclitaxel followed by AC)
Study: 32053137
Drug: Standard neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard neoadjuvant chemotherapy (NACT)
Study: 32101663
Drug: Pembrolizumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab plus neoadjuvant chemotherapy
Study: 34389558
Drug: Nivolumab (NIVO)
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab (NIVO) alone or in combination with ipilimumab (IPI) or IPI alone
Study: 32599652
Drug: Vutrisiran (5-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vutrisiran (5-300 mg)
Study: 33952216
Drug: 5% TTO
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% TTO gel adjunctive to SRP
Study: 33753755
Drug: Daily training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily training regimen over 5 days
Study: 34158656
Drug: Intravenous secretin
Normalized name: Secretin
DrugBank: Secretin human (DB09532)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous secretin
Study: 35169007
Drug: Nerinetide treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerinetide treatment
Study: 35294778
Drug: Evolocumab monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab monotherapy
Study: 35294778
Drug: Combined intervention
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined intervention groups (Evolocumab and Atorvastatin)
Study: 35294778
Drug: Control (Atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Atorvastatin and Evolocumab)
Study: 32888185
Drug: MOGS (myrtle
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOGS (myrtle and oak gall suppository)
Study: 36449413
Drug: Lecanemab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lecanemab (10 mg/kg every 2 weeks)
Study: 36742203
Drug: Bright light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright light therapy
Study: 33387727
Drug: Afatinib 40
Normalized name: afatinib 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afatinib 40 mg orally, once-daily, until disease progression or voluntary withdrawal
Study: 34673898
Drug: Ranibizumab injections
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab injections for PDR
Study: 35511184
Drug: Bortezomib (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib (1 mg/m2 IV) on days -6, -3, +1, and +4 and melphalan (200 mg/m2 IV) on day -2 (Bor-HDM)
Study: 35511184
Drug: High-dose melphalan
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose melphalan alone (200 mg/m2 IV) (HDM)
Study: 37194567
Drug: Weekly POEM
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly POEM for 7 weeks
Study: 32359490
Drug: Rucaparib (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rucaparib (600 mg twice daily)
Study: 35298906
Drug: Chemotherapy (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (administered per institutional guidelines)
Study: 35298906
Drug: Chemotherapy (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (in intention-to-treat population)
Study: 32792446
Drug: Lanreotide 120
Normalized name: LANREOTIDE 120MG INJ,SUSP,SA SYRINGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide 120 mg, administered as subcutaneous injections every 28 days for 72 weeks
Study: 32792446
Drug: Placebo, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, administered as subcutaneous injections every 28 days for 72 weeks
Study: 32792446
Drug: Lanreotide 120
Normalized name: LANREOTIDE 120MG INJ,SUSP,SA SYRINGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide 120 mg
Study: 33878969
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no experimental treatment)
Study: 33971295
Drug: Sit-stand desk
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sit-stand desk attachment, wrist-worn activity prompter, behavioral counseling every two weeks, and twice-weekly automated text messages
Study: 34006559
Drug: Treatment at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment at the hospitals
Study: 36315180
Drug: Using assistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Using assistance for medications
Study: 33220426
Drug: GLS-guided cardioprotective
Normalized name: GL-2045
DrugBank: GL-2045 (DB16971)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLS-guided cardioprotective therapy (CPT) initiation based on ≥12% relative reduction in GLS (n=166)
Study: 33220426
Drug: EF-guided cardioprotective
Normalized name: Klor-Con/EF
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EF-guided cardioprotective therapy (CPT) initiation based on >10% absolute reduction of LVEF (n=165)
Study: 34624757
Drug: D2 (capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: D2 (capecitabine 1800 mg + cyclophosphamide 80 mg)
Study: 34624757
Drug: D3 (capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: D3 (capecitabine 2200 mg + cyclophosphamide 100 mg)
Study: 34624757
Drug: D1 (capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: D1 (capecitabine 1400 mg + cyclophosphamide 60 mg)
Study: 35670115
Drug: iv metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv metoclopramide (0.2 mg/kg) and placebo
Study: 35670115
Drug: iv metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: iv metoclopramide (0.2 mg/kg) and ketorolac (0.5 mg/kg)
Study: 32035876
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of XueShuanTong (150 mg/person)
Study: 32035876
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of XueShuanTong (150 mg/person)
Study: 34639560
Drug: Concurrent Resistance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent Resistance Training (CRT) program
Study: 32048134
Drug: Sn150 kVp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sn150 kVp group (1/2th radiation dose level/150 kVp with a tin filter/2.34 mGy)
Study: 32048134
Drug: Sn100 kVp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sn100 kVp group (1/10th radiation dose level/100 kVp with a tin filter/0.47 mGy)
Study: 32048134
Drug: 120 kVp
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 kVp group (standard radiation dose/tube voltage, 120 kVp/CT volume dose index, 4.68 mGy)
Study: 35849051
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy using Ayres Sensory Integration
Study: 35198576
Drug: Group RD1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group RD1: 20 mL of 0.5% ropivacaine with 5 mg of dexamethasone and 0.5 μg·kg−1 DEX
Study: 35198576
Drug: Group RD2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group RD2: 20 mL of 0.5% ropivacaine with 5 mg of dexamethasone and 1 μg·kg−1 DEX
Study: 35229220
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (Paracetamol given 1 hour before debonding)
Study: 35193665
Drug: Tengfu Jiangya
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tengfu Jiangya tablet (TJT) combined with valsartan/amlodipine (Val/Aml) 80/5 mg
Study: 35193665
Drug: Placebo combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo combined with valsartan/amlodipine (Val/Aml) 80/5 mg
Study: 33664472
Drug: sucrose 24%
Approvals — FDA: no, EMA: no, PMDA: no
Description: sucrose 24% gel with non‐nutritive sucking
Study: 36038181
Drug: BDQ, Pa
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDQ, Pa and LZD 600 mg daily for 26 weeks (Control arm)
Study: 36038181
Drug: BDQ, Pa
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDQ, Pa and LZD 600 mg for 9 weeks followed by 300 mg for 17 weeks (Intervention arm 2)
Study: 36038181
Drug: BDQ, Pa
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDQ, Pa and LZD 600 mg for 13 weeks followed by 300 mg for 13 weeks (Intervention arm 3)
Study: 34412146
Drug: Traditional approaches
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional approaches for quality control of herbal medicines
Study: 34412146
Drug: Compound-oriented approach
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound-oriented approach
Study: 36972286
Drug: Etodolac 200
Normalized name: etodolac 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac 200 mg (single dose)
Study: 36972286
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg (single dose)
Study: 36972286
Drug: Etodolac 200
Normalized name: etodolac 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac 200 mg (four-fold dose)
Study: 36972286
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg (four-fold dose)
Study: 33063412
Drug: Telemedical intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telemedical intervention (TM) using non-invasive devices for daily monitoring of electrocardiogram, blood pressure, and body weight; duration: 12 months.
Study: 35810769
Drug: pTBI +
Approvals — FDA: no, EMA: no, PMDA: no
Description: pTBI + hNSCs at maximum tolerated dose (MTD)
Study: 32238172
Drug: UA-ADRCs (11.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: UA-ADRCs (11.4 × 10^6 cells in 5 mL liquid; mean cell viability: 88%)
Study: 32238172
Drug: Corticosteroid injection
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid injection (80 mg of methylprednisolone plus 3 mL of 0.25% bupivacaine)
Study: 34868484
Drug: Online Narrative
Normalized name: FILTER,SUCTION,INLINE #FHBF200S
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online Narrative Exposure Therapy (eNET) - 8-12 sessions of 90 minutes each conducted via video calls with trained paraprofessionals.
Study: 32075845
Drug: Supplement combination
Normalized name: dietary supplement combination no.28
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplement combination containing Boswellia serrata extract, pine bark extract, methylsulfonylmethane, and curcumin
Study: 33617972
Drug: Supplement combination
Normalized name: dietary supplement combination no.28
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplement combination
Study: 32153793
Drug: NT‐proBNP ≥900 ng/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT‐proBNP ≥900 ng/L
Study: 32152495
Drug: Maternal antidepressant
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal antidepressant use during pregnancy
Study: 32152495
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no antidepressant use)
Study: 32065359
Drug: Rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 10 mg once daily
Study: 32382556
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam (MID)
Study: 32389012
Drug: Runzaozhiyang capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Runzaozhiyang capsules (RZZYC)
Study: 32830802
Drug: Serious game
Normalized name: clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Serious game for Symptom Self‐Management Training for Chemotherapy-Induced Nausea and Vomiting (CINV)
Study: 39320582
Drug: Tofacitinib (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib (all doses)
Study: 35816716
Drug: Beetroot juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot juice (BRJ): 140 mL; ∼8 mmol nitrate
Study: 35816716
Drug: Prune juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prune juice (CON): 166 mL; < 0.01 mmol nitrate
Study: 32826167
Drug: Allogeneic adipose-derived
Normalized name: human adipose preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic adipose-derived mesenchymal stem cells injection with standard diabetic wound care
Study: 35211042
Drug: Bumetanide (max
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bumetanide (max 1 mg twice daily)
Study: 35443387
Drug: Ramipril (5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (5mg twice daily)
Study: 36183733
Drug: Fulvestrant (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fulvestrant (500 mg intramuscularly on day 1 of each 28‐day cycle and on day 15 of cycle 1) and palbociclib (125 mg orally once per day on days 1‐21 of a 28‐day cycle)
Study: 36183733
Drug: Aromatase inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitor (2·5 mg letrozole, 1 mg anastrozole, or 25 mg exemestane, orally once per day, taken continuously) and palbociclib (125 mg orally once per day on days 1‐21 of a 28‐day cycle)
Study: 36183733
Drug: Aromatase inhibitor
Normalized name: Aromatase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitor and palbociclib group
Study: 33129609
Drug: AV7909 (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: AV7909 (three doses at Days 1, 15, and 29)
Study: 33129609
Drug: AV7909 (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: AV7909 (two doses at Days 1 and 29)
Study: 32650518
Drug: Trimebutine maleate
Normalized name: Trimebutine maleate
DrugBank: Trimebutine (DB09089)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimebutine maleate (TM) 300 mg twice per day (BID) for 4 weeks
Study: 34857226
Drug: n-3 PUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFA (3680 mg/day)
Study: 34672349
Drug: Intravenous trabectedin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous trabectedin (1.5 mg/m2 every 3 weeks)
Study: 33080817
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CG) maintaining daily routine
Study: 33324478
Drug: Intensive cytarabine‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive cytarabine‐based chemotherapy
Study: 35865342
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium sustained-release tablets
Study: 33734289
Drug: weekly irinotecan/carboplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: weekly irinotecan/carboplatin for 6 weeks plus TRT of 60 Gy followed by 2 courses of irinotecan/carboplatin consolidation
Study: 33734289
Drug: weekly paclitaxel/carboplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: weekly paclitaxel/carboplatin for 6 weeks plus TRT of 60 Gy followed by 2 courses of paclitaxel/carboplatin consolidation
Study: 36254912
Drug: Recombinant erythropoietin
Normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant erythropoietin (500 IU/kg) administered one to three days before surgery
Study: 34376153
Drug: Low-dose sodium
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose sodium thiopental (5 mg/kg)
Study: 34376153
Drug: High-dose sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose sodium thiopental (7 mg/kg)
Study: 36152018
Drug: Oral function
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral function intervention (EG) including oral exercise and preventive oral care, with a reminder phone call every 2 weeks
Study: 36152018
Drug: Oral function
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral function intervention (EG)
Study: 32905615
Drug: Metronidazole (MTZ)
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metronidazole (MTZ) + Amoxicillin (AMX) + Scaling and Root Planing (SRP)
Study: 35442211
Drug: Deep Q-learning
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep Q-learning (DQL) treatment decisions
Study: 32942346
Drug: Cariprazine 1.5-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cariprazine 1.5-3 mg/d